Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis
about
Gender analysis of moxifloxacin clinical trialsPenetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections.Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis.Rapid drug tolerance and dramatic sterilizing effect of moxifloxacin monotherapy in a novel hollow-fiber model of intracellular Mycobacterium kansasii disease.Mycobacterial brain tuberculomas due to Bacille Calmette-Guérin intravesical chemotherapy for bladder cancer: A case report and literature review.Low Serum Concentrations of Moxifloxacin, Prothionamide, and Cycloserine on Sputum Conversion in Multi-Drug Resistant TB.High-performance liquid chromatography assay for moxifloxacin in brain tissue and plasma: validation in a pharmacokinetic study in a murine model of cerebral listeriosis.Tuberculous meningitis: diagnosis and treatment overview.Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing.Standardized Methods for Enhanced Quality and Comparability of Tuberculous Meningitis Studies.Concentration-Dependent Synergy and Antagonism of Linezolid and Moxifloxacin in the Treatment of Childhood Tuberculosis: The Dynamic Duo.Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks.Moxifloxacin population pharmacokinetics and model-based comparison of efficacy between moxifloxacin and ofloxacin in African patients.Association of gyrA/B mutations and resistance levels to fluoroquinolones in clinical isolates of Mycobacterium tuberculosis.Treatment of bacterial meningitis: an update.Targeting multidrug-resistant tuberculosis (MDR-TB) by therapeutic vaccines.Clinical pharmacokinetics of antibacterials in cerebrospinal fluid.Bacterial meningitis: new therapeutic approaches.Treatment strategies for central nervous system infections: an update.Bacterial meningitis: an update of new treatment options.Pharmacokinetic/pharmacodynamic-based optimization of levofloxacin administration in the treatment of MDR-TB.Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB.Diagnosis and treatment of paediatric tuberculosis: An insight review.A Review of Moxifloxacin for the Treatment of Drug-Susceptible Tuberculosis.Septic cavernous sinus thrombosis caused by tuberculosis infection.Overton's rule helps to estimate the penetration of anti-infectives into patients' cerebrospinal fluidMoxifloxacin: An Alternative to Ethambutol for the Treatment of Presumed Ocular Tuberculosis.Pharmacokinetics of Bedaquiline in Cerebrospinal Fluid and Serum in Multidrug-Resistant Tuberculous Meningitis.Systemic fluoroquinolone prescriptions for hospitalized children in Belgium, results of a multicenter retrospective drug utilization study.Tuberculous meningitisAcquired Drug Resistance: We Can Do More Than We Think!
P2860
Q28538319-8978B2D8-54BA-45B1-A01E-47EA12E0BE74Q34142328-C3D7F114-7C4D-407C-A785-045EAE69C601Q35065890-E9BF3C52-2ADE-4162-B55C-26F910E21F5EQ35169089-53078199-D0B2-46B5-B630-54C58588B739Q35434020-CEA72201-A92E-4231-AFFC-A3477795D94AQ35778303-6DB87288-17D6-4C36-A7CF-CA1B49C65513Q35909500-0B895409-C7BB-45DD-9AA9-1C05AAEA1843Q35910242-41B02CDE-D1FE-449A-BB3E-297D7750DE39Q36083619-0A7755E7-77FF-4614-861D-4CFAD32C5651Q36273077-344A83CE-93F3-4475-967A-8AA2AE11E9D6Q37339276-EF4A04FD-AD73-4751-8F27-C61777331327Q37339290-CC384B68-7A8F-455F-9B3A-ACDA6786090DQ37544479-361DA6AA-A2CE-4E5A-BD9F-971CE78EFC90Q37682208-9C182644-6DBD-40F1-A253-604C28F9EFAEQ38044024-DE40E483-D962-4B35-A460-75BB4EFCFC10Q38059150-30CE4648-3DFD-4B69-9DC1-86E173D954E3Q38100704-5F6BA990-E742-4174-B860-D2C59A281234Q38145360-49B22641-E74C-458E-928C-13E6900D212FQ38261298-8DBF5053-C910-4B2E-87D3-CDCC2CBC5C33Q38570487-D4DF00B3-2647-4AA2-BEEF-5A5920012EF1Q38845761-07A40346-2E35-419E-8A14-0C557D9354A5Q38973113-D443459D-1DD1-4532-B8C4-E2D00E3C9921Q39209677-B488AB53-A08E-40C6-8127-AC63EC761E11Q39456569-170BDDFD-36AE-49E8-907D-926B4A830DD5Q40181438-9D705166-EB13-4F42-9BA3-4C50AC191E43Q40600560-44D43532-1C28-4ED5-8325-4A7F7A126D73Q41083720-9FB323A0-AD42-4AF3-AF83-10F2A6D7F6A4Q53810580-7309E0F7-51C7-402C-B476-BC91D4CAF3CEQ54268209-F18F361D-6067-4DEA-B67C-64B6E1E88213Q57827115-16FD4C98-4EC3-4866-B204-307481B9BF23Q58033436-D5948562-767E-4EFA-A69E-587B4BB75FDE
P2860
Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis
description
2009 nî lūn-bûn
@nan
2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Pharmacokinetics of moxifloxac ...... ts with tuberculous meningitis
@ast
Pharmacokinetics of moxifloxac ...... ts with tuberculous meningitis
@en
Pharmacokinetics of moxifloxac ...... ts with tuberculous meningitis
@nl
type
label
Pharmacokinetics of moxifloxac ...... ts with tuberculous meningitis
@ast
Pharmacokinetics of moxifloxac ...... ts with tuberculous meningitis
@en
Pharmacokinetics of moxifloxac ...... ts with tuberculous meningitis
@nl
prefLabel
Pharmacokinetics of moxifloxac ...... ts with tuberculous meningitis
@ast
Pharmacokinetics of moxifloxac ...... ts with tuberculous meningitis
@en
Pharmacokinetics of moxifloxac ...... ts with tuberculous meningitis
@nl
P2093
P921
P3181
P356
P1476
Pharmacokinetics of moxifloxac ...... ts with tuberculous meningitis
@en
P2093
D van Soolingen
G J Luijckx
H J Bökkerink
J W C Alffenaar
R E Aarnoutse
R van Altena
T S van der Werf
P304
P3181
P356
10.1086/605576
P407
P577
2009-10-01T00:00:00Z